FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089587613> ?p ?o ?g. }

• W3089587613 endingPage "1256" @default.
• W3089587613 startingPage "1247" @default.
• W3089587613 abstract "Anti-Ly6E-seco-cyclopropabenzindol-4-one dimer antibody-drug conjugate (ADC) has been reported to form an adduct with α1-microglobulin (A1M) in animal plasma, but with unknown impact on ADC PK and tissue distribution. In this study, we compared the PK and tissue distribution of anti-Ly6E ADC with unconjugated anti-Ly6E mAb in rodents and monkeys. For PK studies, animals received an intravenous administration of anti-Ly6E ADC or unconjugated anti-Ly6E mAb. Plasma samples were analyzed for total antibody (Tab) levels and A1M adduct formation. PK parameters were generated from dose-normalized plasma concentrations. Tissue distribution was determined in tumor-bearing mice after a single intravenous dosing of radiolabeled ADC or mAb. Tissue radioactivity levels were analyzed using a gamma counter. The impact of A1M adduct formation on target cell binding was assessed in an in vitro cell binding assay. The results show that ADC Tab clearance was slower than that of mAb in mice and rats but faster than mAb in monkeys. Correspondingly, the formation of A1M adduct appeared to be faster and higher in mice, followed by rats, and slowest in monkeys. Although ADC tended to show an overall lower distribution to normal tissues, it had a strikingly reduced distribution to tumors compared with mAb, likely due to A1M adduct formation interfering with target binding, as demonstrated by the in vitro cell binding assay. Together, these data 1) demonstrate that anti-Ly6E ADC that forms A1M adduct had slower systemic clearance with strikingly reduced tumor distribution and 2) highlight the importance of selecting an appropriate linker-drug for successful ADC development. SIGNIFICANCE STATEMENT: Anti-lymphocyte antigen 6 complex, locus E, ADC with seco-cyclopropabenzindol-4-one-dimer payload formed adduct with A1M, which led to a decrease in systemic clearance but also attenuated tumor distribution. These findings demonstrate the importance of selecting an appropriate linker-drug for ADC development and also highlight the value of a mechanistic understanding of ADC biotransformation, which could provide insight into ADC molecule design, optimization, and selection." @default.
• W3089587613 created "2020-10-08" @default.
• W3089587613 creator A5014057621 @default.
• W3089587613 creator A5017526947 @default.
• W3089587613 creator A5030816359 @default.
• W3089587613 creator A5070060056 @default.
• W3089587613 creator A5072518011 @default.
• W3089587613 creator A5075622397 @default.
• W3089587613 creator A5080545613 @default.
• W3089587613 creator A5087570789 @default.
• W3089587613 date "2020-10-05" @default.
• W3089587613 modified "2023-10-16" @default.
• W3089587613 title "Anti–Lymphocyte Antigen 6 Complex, Locus E-<i>Seco</i>-Cyclopropabenzindol-4-One-Dimer Antibody-Drug Conjugate That Forms Adduct with<i>α</i>1-Microglobulin Demonstrates Slower Systemic Antibody Clearance and Reduced Tumor Distribution in Animals" @default.
• W3089587613 cites W1555185942 @default.
• W3089587613 cites W1587403680 @default.
• W3089587613 cites W1597245923 @default.
• W3089587613 cites W1964083777 @default.
• W3089587613 cites W1984892288 @default.
• W3089587613 cites W1993966288 @default.
• W3089587613 cites W2025382759 @default.
• W3089587613 cites W2064424529 @default.
• W3089587613 cites W2097200325 @default.
• W3089587613 cites W2098749503 @default.
• W3089587613 cites W2116150122 @default.
• W3089587613 cites W2171368669 @default.
• W3089587613 cites W2226317100 @default.
• W3089587613 cites W2338841302 @default.
• W3089587613 cites W2783629021 @default.
• W3089587613 cites W2787698051 @default.
• W3089587613 cites W2788615048 @default.
• W3089587613 cites W2800948756 @default.
• W3089587613 cites W2890978005 @default.
• W3089587613 cites W2906851106 @default.
• W3089587613 cites W2909779618 @default.
• W3089587613 cites W2912531885 @default.
• W3089587613 cites W2921589168 @default.
• W3089587613 cites W2936267551 @default.
• W3089587613 cites W2946203866 @default.
• W3089587613 cites W4210394199 @default.
• W3089587613 doi "https://doi.org/10.1124/dmd.120.000145" @default.
• W3089587613 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33020064" @default.
• W3089587613 hasPublicationYear "2020" @default.
• W3089587613 type Work @default.
• W3089587613 sameAs 3089587613 @default.
• W3089587613 citedByCount "3" @default.
• W3089587613 countsByYear W30895876132020 @default.
• W3089587613 countsByYear W30895876132021 @default.
• W3089587613 countsByYear W30895876132022 @default.
• W3089587613 crossrefType "journal-article" @default.
• W3089587613 hasAuthorship W3089587613A5014057621 @default.
• W3089587613 hasAuthorship W3089587613A5017526947 @default.
• W3089587613 hasAuthorship W3089587613A5030816359 @default.
• W3089587613 hasAuthorship W3089587613A5070060056 @default.
• W3089587613 hasAuthorship W3089587613A5072518011 @default.
• W3089587613 hasAuthorship W3089587613A5075622397 @default.
• W3089587613 hasAuthorship W3089587613A5080545613 @default.
• W3089587613 hasAuthorship W3089587613A5087570789 @default.
• W3089587613 hasBestOaLocation W30895876131 @default.
• W3089587613 hasConcept C108204754 @default.
• W3089587613 hasConcept C110121322 @default.
• W3089587613 hasConcept C112705442 @default.
• W3089587613 hasConcept C134306372 @default.
• W3089587613 hasConcept C153911025 @default.
• W3089587613 hasConcept C159654299 @default.
• W3089587613 hasConcept C178790620 @default.
• W3089587613 hasConcept C185592680 @default.
• W3089587613 hasConcept C197336794 @default.
• W3089587613 hasConcept C202751555 @default.
• W3089587613 hasConcept C203014093 @default.
• W3089587613 hasConcept C2777325958 @default.
• W3089587613 hasConcept C33923547 @default.
• W3089587613 hasConcept C542903549 @default.
• W3089587613 hasConcept C55493867 @default.
• W3089587613 hasConcept C86803240 @default.
• W3089587613 hasConcept C98274493 @default.
• W3089587613 hasConceptScore W3089587613C108204754 @default.
• W3089587613 hasConceptScore W3089587613C110121322 @default.
• W3089587613 hasConceptScore W3089587613C112705442 @default.
• W3089587613 hasConceptScore W3089587613C134306372 @default.
• W3089587613 hasConceptScore W3089587613C153911025 @default.
• W3089587613 hasConceptScore W3089587613C159654299 @default.
• W3089587613 hasConceptScore W3089587613C178790620 @default.
• W3089587613 hasConceptScore W3089587613C185592680 @default.
• W3089587613 hasConceptScore W3089587613C197336794 @default.
• W3089587613 hasConceptScore W3089587613C202751555 @default.
• W3089587613 hasConceptScore W3089587613C203014093 @default.
• W3089587613 hasConceptScore W3089587613C2777325958 @default.
• W3089587613 hasConceptScore W3089587613C33923547 @default.
• W3089587613 hasConceptScore W3089587613C542903549 @default.
• W3089587613 hasConceptScore W3089587613C55493867 @default.
• W3089587613 hasConceptScore W3089587613C86803240 @default.
• W3089587613 hasConceptScore W3089587613C98274493 @default.
• W3089587613 hasIssue "12" @default.
• W3089587613 hasLocation W30895876131 @default.
• W3089587613 hasOpenAccess W3089587613 @default.
• W3089587613 hasPrimaryLocation W30895876131 @default.
• W3089587613 hasRelatedWork W131348366 @default.
• W3089587613 hasRelatedWork W1975407439 @default.

• next